PRME
Prime Medicine·NASDAQ
--
--(--)
--
--(--)
3.84 / 10
Netural
Only one analyst rates PRME a Buy, but with 0% historical win rate and –9.38% average return, indicating weak coverage. Fund‑flow score is 7.68 (good); overall inflow ~49% despite negative trend, while large‑cap investors show positive net inflow.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
0%
Buy
100%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-12
InstitutionOppenheimer
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for PRME?
- PRME holds a Bearish analyst rating, with 100% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 3.84/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
